ReviewTherapeutic advances in medical oncology2024
Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.
Review in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Role of Surgery on the Treatment of Primary Pulmonary Sarcomas and Pulmonary Sarcomatoid Carcinoma.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Surgical Resection Remains the Cornerstone for Lung Malignancies with Sarcomatoid Components.Annals of surgical oncology · 2026Article
- Long survival of PD-L1-positive mediastinal sarcomatoid carcinoma after immunotherapy and anti-angiogenic target therapy: A case report.Oncology letters · 2026Article
- Article
- A Population-Based Nomogram for Predicting Overall Survival in Pulmonary Sarcomatoid Carcinoma With Real-World External Validation.Cancer medicine · 2026Article
- Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review.Frontiers in oncology · 2026Article
- Establishment, functional dissection, and single-cell transcriptomal characteristics of patient-derived pulmonary sarcomatoid carcinoma organoids.Frontiers in oncology · 2026Article
- Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Article
- Exceptional Response to Immunotherapy-based Treatment in CompoundJournal of immunotherapy and precision oncology · 2025Article
- Pulmonary Sarcomatoid Carcinoma Initially Misdiagnosed as Aspergillosis: A Diagnostic Challenge.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer, is highly malignant and has a poor prognosis. Treatments for PSC are presently limited. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Surgical intervention is the preferred option for early-stage PSC patients, whereas chemotherapy, radiotherapy, immunotherapy, and other targeted therapies are recommended for advanced PSC patients. Targeted therapy is only effective in a small number of PSC patients. The initial efficacy of immune checkpoint inhibitors has been acceptable in patients with advanced PSC; therefore, much attention on related biomarkers has been sought. This article aimed to review the research progress of PSC immunotherapy and related diagnostic and prognostic biomarkers in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.